These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21821852)

  • 1. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
    Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
    Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
    Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
    Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial.
    Blomström P; Ekman M; Lundqvist CB; Calvert MJ; Freemantle N; Lönnerholm S; Wikström G; Jönsson B
    Eur J Heart Fail; 2008 Sep; 10(9):869-77. PubMed ID: 18684664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.
    Poggio R; Augustovsky F; Caporale J; Irazola V; Miriuka S
    Int J Technol Assess Health Care; 2012 Oct; 28(4):429-35. PubMed ID: 23006489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac resynchronization therapy: a cost or an investment?
    Boriani G; Mantovani LG; Biffi M; Schalij MJ; Martignani C; Leclercq C; Bax JJ; Auricchio A
    Europace; 2011 May; 13 Suppl 2():ii32-8. PubMed ID: 21518747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain.
    Almenar L; Díaz B; Quesada A; Crespo C; Martí B; Mealing S; Linde C; Daubert C
    Int J Technol Assess Health Care; 2013 Apr; 29(2):140-6. PubMed ID: 23552131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
    Banz K;
    Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyssynchrony, contractile function, and response to cardiac resynchronization therapy.
    Knappe D; Pouleur AC; Shah AM; Cheng S; Uno H; Hall WJ; Bourgoun M; Foster E; Zareba W; Goldenberg I; McNitt S; Pfeffer MA; Moss AJ; Solomon SD;
    Circ Heart Fail; 2011 Jul; 4(4):433-40. PubMed ID: 21602574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cardiac resynchronization therapy cost-effective?
    Boriani G; Biffi M; Martignani C; Valzania C; Diemberger I; Bertini M; Domenichini G; Ziacchi M; Branzi A
    Europace; 2009 Nov; 11 Suppl 5():v93-7. PubMed ID: 19861398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.
    Bertoldi EG; Rohde LE; Zimerman LI; Pimentel M; Polanczyk CA
    Int J Cardiol; 2013 Mar; 163(3):309-315. PubMed ID: 21704396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
    Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of a randomized trial of biventricular pacing in Canada.
    Bentkover JD; Dorian P; Thibault B; Gardner M
    Pacing Clin Electrophysiol; 2007 Jan; 30(1):38-43. PubMed ID: 17241313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure.
    Tomini F; Prinzen F; van Asselt AD
    Eur J Health Econ; 2016 Dec; 17(9):1159-1172. PubMed ID: 26728985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.